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Abstract. Background: Prostate cancer (PC) represents
the most frequently diagnosed cancer in men. Exposure to
infectious agents has been considered to induce prostatic
inflammation and cancerous transformation. Controversial
data exist concerning the role of the human polyomaviruses
BK (BKV) and JC (JCV) in PC etiology. Therefore, a
possible association between these polyomaviruses and PC
was investigated. Materials and Methods: Urine, blood and
fresh prostatic tissue specimens were collected from 26
patients with PC. The presence of BKV and JCV, the
possible non-coding control region (NCCR) variations and
the genotyping analysis of viral protein 1 (VP1) of both
viruses were assessed. Results: Data showed a preferential
viral re-activation in the urinary compartment and a
statistically significant prevalence of JC viruria and of BKV
in PC tissues. A BKV DDP-like NCCR sequence was
isolated in two patients, whereas JCV NCCR was
consistently of an archetypal structural organization. A
prevalence of the European genotypes was observed for
both viruses. Conclusion: Our data demonstrated the
presence of JCV DNA in 14/24 (58.3%) cancerous prostatic
tissue specimens, confirming the results obtained in a
previous study, in which JCV has been defined as common
inhabitant of the prostate, and opening the discussion about
its potential role in PC.
With an estimated 220,800 new cases and 27,540 deaths in the
United States during 2015, prostate cancer (PC) represents the
second leading cause of cancer-related death and the most
frequently diagnosed cancer in men aside from skin cancer (1).
Along with benign prostatic hyperplasia (BPH), the most
frequent urological diagnosis in elderly males, PC is a significant
health concern that may become increasingly prevalent in the
coming years in relation to the gradual aging of the population
(2). In fact, increasing age is one of the well-established risk
factors that contribute to the development of PC (1).
Currently, there is both experimental and clinical evidence
validating the hypothesis that inflammation may contribute
to the pathogenesis of PC (3). Inflammation has been
associated with about 20% of all human cancer in adults by
causing genomic damage (2, 4-7). Infection is a known
major cause of inflammation, and can lead to chronic
inflammation of the prostate. In fact, different infectious
agents (for instance sexually transmitted bacteria and
viruses) have been shown to affect the prostate, which is a
sterile organ, inducing prostatic inflammation (2, 5, 8-11)
and eventually cancerous transformation of the prostate
gland, mainly when this phenomenon is prolonged (3).
Several non-sexually transmitted infectious agents have
also been investigated in relation to prostate carcinogenesis,
including those of the genitourinary tract, such as the human
polyomavirus BK (BKV) (10). This urotheliotrophic virus
exhibits oncogenic properties via the large T antigen, which
can bind and block the p53 tumor-suppressor and the
retinoblastoma protein (pRb) (12). Because of the long-term
latency, genitourinary tropism and potential oncogenicity that
are associated with BKV, several articles have investigated its
possible link to prostate cancer, with controversial results (13-
25). However, the possibility of 'hit-and-run' carcinogenic
mechanisms induced by BKV cannot be excluded (18).
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BKV genome is functionally divided into two coding regions:
an early region, which codes for the T antigens (large and
small), and a late region, which codes for the late proteins (agno
and capsid proteins). It also presents a non-coding control
region (NCCR), which contains several cis-acting sequences
important for viral DNA replication [promoter/enhancer
elements, binding sites for T antigens, origin of replication (O-
block, 142 bp)], and sequences containing the binding sites for
cellular transcriptional factors involved in transcriptional
regulation of both the early and the late genes (26). The NCCR
of the proposed archetypal BK strain (WW) has been arbitrarily
divided into four transcriptional factor binding sequence blocks,
called P (68 bp), Q (39 bp), R (63 bp), and S (63 bp) (27). The
different BKV strains display a marked heterogeneity in their
NCCRs due to point mutations, deletions, duplications, and re-
arrangements in this region. These re-arrangements may play
an important role in virus replication, allowing the virus to adapt
to ongoing changes within the host cell environment, by
increasing or decreasing the number or the affinities of host
transcription factor binding sites (28). Genetically re-arranged
BKV variants (e.g. URO1) might exist in the urinary tract and
be responsible for neoplastic transformation of prostate cells
(29). Therefore, BKV has been indicated as a potential cofactor
in the earliest stages of PC (18). In fact,  our previous studies
also demonstrated that the presence of BKV and its variants in
transformed cells does not exclude viral pressure in cell
immortalization (19, 25).
Regarding the human polyomavirus JC (JCV), despite its
high homology with BKV, the presence of the oncogenic
protein large T antigen and its latency site in the
genitourinary tract, only a few studies have investigated the
possible role of this virus in relation to PC, obtaining
conflicting results (13, 16, 21, 24). The JCV NCCR is a
highly variable region and contains many neurotropic and
neurovirulence determinants. Based on the structure of this
region, the JCV NCCR forms have been classified into four
types (30). Type II-S has a sequence made up of boxes A
(25 bp), B (23 bp), C (55 bp), D (66 bp), E (18 bp) and F
(69 bp), as seen in the archetype CY (31). Type I-S is
composed of boxes A (25 bp), C (55 bp) and E (18 bp),
forming a single 98-bp unit, and box F (69 bp). Conversely,
type I-R has repeats of this 98 bp unit with various
deletions, as seen in JCV Mad-1 and Mad-4 strains (32-33),
respectively. Finally, type II-R has repeats of this 98 bp unit
and inserts with various mutations, also called rearranged
NCCRs. In types I-R and II-R is always present the box F
(33). The NCCR of the JCV Mad-1 strain has been detected
in the prostate gland associated with the urinary tract
together with different NCCR sequences, suggesting that the
prostate may be inhabited by more than one JCV strain or
NCCR variant (13).
Taking into account these assumptions, the aims of this
molecular study were: (i) to investigate whether the presence
of BKV might be linked to PC progression, (ii) to assess a
possible association between JCV and PC, considering its
high homology with BKV, and (iii) to determine whether a
specific NCCR configuration and a particular viral genotype
were associated with a normal or cancerous prostate cellular
environment. In particular, the presence of both human
polyomaviruses was evaluated in fresh prostatic
adenocarcinoma and in benign tissue specimens, in urine,
plasma and peripheral blood mononuclear cells (PBMCs)
collected from each patient enrolled in this study.
Materials and Methods
Study population. Fresh prostate tissue specimens, blood and urine
samples were obtained from 26 patients (mean age=66 years;
range=51-75 years), without a history of neoplastic diseases. These
subjects underwent radical retropubic prostatectomy for prostate
cancer treatment at the Department of Obstetrics, Gynecology and
Urological Sciences of the Umberto I General Hospital (Rome,
Italy) between December 2011 to April 2013 (Table I). Enrollment
was achieved according to the following criteria: (i) no previous
hormonal or radiation therapy, (ii) no previous surgery of the
prostate gland, and (iii) histologically-proven PC by biopsy and
confirmed by radical retropubic prostatectomy.
Prostate specimens, obtained at surgery, were analyzed for areas
of relatively pure prostatic adenocarcinoma, or benign tissue, which
served as benign controls, and processed independently. All tissue
samples were immediately frozen and stored at −80˚C until DNA
extraction.
All patients enrolled in this study provided written informed
consent with guarantees of confidentiality.
Clinical specimens collection and processing. Standard laboratory
procedures for sterile DNA extraction and polymerase chain
reaction (PCR) were practiced for all specimens, including the use
of ultra-pure, UV irradiated and autoclaved water, autoclaving of all
tubes and equipment, tissue processing under a laminar flow, UV
irradiated hood, the use of filter-barrier pipette tips, etc.
Fresh urine specimens, collected without preservatives, were
centrifuged at 1.376 × g for 10 min at 4˚C. DNA for molecular
analysis was extracted from the pellet of each specimen using the
QIAamp® DNA Mini Kit (QIAGEN S.p.A, Milan, Italy) according
to the manufacturer’s instructions.
Blood samples, collected in 7-ml Vacutainer® tubes containing
EDTA (BD Becton Dickinson S.p.A, Milan, Italy), were centrifuged
at 1.376×g for 10 min and DNA was extracted from 200 μl of
plasma using the QIAamp® DNA Mini Kit (QIAGEN S.p.A).
PBMCs were isolated from whole blood using the standard Ficoll
Hypaque density gradient centrifugation technique (34) and the
number of viable leukocytes was determined by trypan blue
exclusion. PBMCs DNA extraction was performed on 106 cells by
the QIAmp® DNA Mini Kit (QIAGEN S.p.A) following the
manufacturer’s instructions.
Small pieces of normal and cancerous prostate tissue specimens
were thawed and processed for DNA extraction using the QIAamp®
DNA Mini Kit (QIAGEN S.p.A) and the recommended tissue
protocol. DNA yield of all samples was determined by measuring
its concentration in the eluate by absorbance at 260 nm and DNA
was stored at −20˚C until use.
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BKV/JCV real-time TaqMan PCR (Q-PCR). DNA extracted from
each sample was tested for BKV and JCV genome and
quantification by two commercial kits: the BKV Q-PCR Alert Kit
and the JCV Q-PCR Alert Kit (ELITechGroup S.p.A, Trezzano S/N,
Milan, Italy). These quantitative assays, based on TaqMan-MGB®
(Minor Groove Binder) technology, were performed using a 7300
real-time PCR system and SDS 1.4 software to analyze the
amplification data (AB Applied Biosystems, Foster City, CA, USA).
The amplification reaction was carried out both for a region of the
gene that encodes BKV and JCV large T antigen and for the
promoter region and 5’UTR of the human beta-globin (β-globin)
gene. β-Globin gene was amplified simultaneously with the target
sequence to verify successful DNA isolation and exclude false-
negative results. All samples were tested in triplicate and the number
of viral copies in each sample was calculated from the standard
curve. The standard curve for these quantitative amplification assays
was obtained using four stabilized serial dilutions at known titer
(range: 102-105 plasmid copies) of a plasmid containing part of the
BKV and JCV large T antigen. For urine and plasma specimens,
BKV and JCV DNA load was expressed as genome equivalents of
viral DNA (gEq)/ml of sample, as genome equivalents (gEq)/106
cells of sample for PBMCs and as genome equivalents (gEq)/mg for
tissues. Standard precautions designed to prevent contamination
during Q-PCR were followed and a no template control (NTC) lane
was included in each run. Both assays were able to quantify
between 10 and 106 DNA copies of the target gene per
amplification reaction (gEq).
PCR for BKV/JCV NCCR and VP1 gene typing region. All samples
positive for viral DNA were subsequently screened for the NCCR
of both viruses by nested-PCR using specific sets of primers (35-
36) in a 9700 GeneAmp® PCR System (AB Applied Biosystems).
To characterize the viral genotype in all BKV/JCV-positive samples,
a PCR amplifying the VP1 typing region of both viruses was carried
out with specific primers for these regions (37-39). All assays
included positive (previously amplifiable BKV or JCV DNA) and
negative (pure water as template) controls to exclude false-positive
and false-negative results. PCR products were detected by
electrophoresis on a GelRed™ (Biotium)-stained 2% agarose gel
and visualized under UV light.
Sequencing of BKV/JCV NCCR and VP1 regions. PCR products
corresponding to the NCCR and VP1 regions were purified before
sequencing to remove excess primers with QIAquick® PCR
purification kit, according to the QIAGEN protocol (40). DNA
sequencing was performed using a dedicated facility (Bio-Fab
research s.r.l., Rome, Italy). All sequences obtained from the NCCR
amplifications were compared to the BKV prototypic NCCR
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Table I. Clinical characteristics of patients with prostate cancer and clinical samples provided.
Patient Age (years) Urine Plasma PBMCs Non-cancer tissue Cancer tissue pTNM Gleason score PSA (ng/ml) Residual tumor 
1 75 P P P P P pT3bNx 7 (3+4) 8 R1 
2 75 NP P P P P pT3aN0 7 (4+3) 7.2 / 
3 70 P P P P P pT2cpNx 6 (3+3) 5 R0 
4 68 P P P P P pT2cNx 7 (3+4) 6.8 R0 
5 60 P P P P P pT2cNx 7 (3+4) 4.8 R0 
6 55 P P P P P pT2cpNx 6 (3+3) 4.5 R0 
7 72 P P P P P pT3aNx 7 (4+3) 9 R0 
8 59 P NP NP P P pT3aNx 7 (3+4) 3.4 R1 
9 61 P P P P P pT2cNx 6 (3+3) 2.5 R0 
10 70 P P P P P pT2cNx 6 (3+3) 2.58 R0 
11 60 P P P P P pT2aNx 7 (3+4) 6 R0 
12 73 P P P P P pT2aNx 6 (3+3) 7 R1 
13 58 P P P P P pT2cNx 6 (3+3) 5.1 R0 
14 51 P P P P P pT2cpNx 6  (3+3) 4.5 R0 
15 71 P P P P P pT3aN0 7  (3+4) 6.88 R0 
16 58 P P P P P pT3aNx  7 (3+4) 17 R1 
17 62 P P P P P pT2cNx 7 (3+4) 4.37  R0 
18 72 P P P P P Deceased Deceased 9.71  / 
19 67 P P P P P pT3apNx  7 (3+4) 3.6  R0 
20 66 P NP NP P P pT3apN0  6 (3+3) 4.56 R0 
21 73 P P P P P pT3apN0 + HGPIN  7 (3+4) 7.10 R0 
22 74 P P P P P pT2cpNx 6 (3+3) 11.7  R0 
23 69 P P P P P pT2cNx 7 (3+4) 6.74  R0 
24 59 NP P P P P pT2cN0 6 (3+3) 10.9 R0 
25 71 P P P P P pT2cNx 6 (3+3) 7.76 R0 
26 73 P P P P P pT3bNx 7 (3+4) 13 R0 
P: Samples provided; NP: no samples provided; PBMCs: peripheral blood mononuclear cells; PSA: prostate-specific antigen; pT2: organ confined;
pT2a: unilateral; pT2b: bilateral; pT3a: extraprostatic extension; pT3b, seminal vesicle invasion; NX: regional lymph nodes could be assessed;  pNX:
regional nodes not sampled; R0: no residual tumor; R1: microscopic residual tumor.  Tumor grade was determined by Gleason score. Tumor staging
was determined by TNM classification (https://cancerstaging.org/).
sequence (41) and to the JCV NCCR of the archetype strain CY
(31) in order to investigate the presence of possible rearrangements
within these regions. Sequences obtained from the amplification of
the VP1 gene typing region of both viruses were classified into
known genotypes/subtypes examining the single nucleotide
polymorphisms (SNPs) within the amplified VP1 coding sequence.
To detect the SNPs by which we have classified our isolates, many
complete VP1 gene sequences belonging to all known BKV
subtypes/subgroups and JCV genotypes were aligned in order to
generate a consensus sequence for each BKV subtype and JCV
genotype (28, 42). Subsequently, we aligned our isolates with the
consensus sequences generated for each BKV subtypes by Anzivino
and colleagues in 2011 (28) and with those reported by Jobes and
colleagues in 2001 for JCV (42). Sequence alignments were
performed with ClustalW2 at the EMBL-EBI website using default
parameters (43).
Statistical analysis. Data were summarized as medians and ranges
or  as the mean, as appropriate. If the Z-test indicated a non-normal
distribution, we used non-parametric test such as Mann-Whitney U-
tests and Kruskal–Wallis tests. Categorical data were analyzed by
using χ2 test and Student’s t-test. p-Values of less than 0.05 were
considered statistically significant.
Results
Evaluation of JC and BK viral load in biological
specimens. This study was conducted on 26 patients with
PC from whom we collected at surgery 52 fresh prostate
specimens (26 benign and 26 cancerous tissue samples), 24
urine and 24 whole blood samples. Regarding human
polyomavirus DNA detection by Q-PCR in urine, BK
viruria was detected in seven out of 24 specimens (29.2%)
with a mean load of 2.97 log10 gEq/ml (range=2.34-4.85
gEq/ml ), whereas JC viruria was found in 15/24 samples
(62.5%) with a mean value of 5.16 log10 gEq/ml
(range=3.43-6.51 gEq/ml) (Table II). Concerning blood
samples, BKV DNA was detected in 6/24 plasma samples
(25%), with a mean viral load of 3.25 log10 gEq/ml
(range=2.44-4.25 gEq/ml), and in two PBMCs specimens
(8.3%) with a load of 1.15 log10 gEq/106 cells
(range=1.11-1.18 gEq/106 cells). JC viremia was found in
two out of 24 samples (8.3%), with a mean load of 3.81
log10 gEq/ml (range=3.76-3.86 gEq/ml), whereas 14/24
specimens (58.3%) were positive for JCV DNA in PBMCs
samples, with a mean value of 1.29 log10 gEq/106 cells
(range=1.11-1.45 gEq/106 cells) (Table II). Finally, in
prostate specimens, BKV was found in 6/26 cancerous
tissue samples (23.1%), with a value of 3.35 log10 gEq/mg
(range=2.26-3.90 gEq/mg), and in one benign tissue
sample, with a value of 1.54 log10 gEq/mg, whereas JCV
DNA was detected both in 14 cancerous and in 14 benign
tissue samples (58.3%), with a mean load of 2.04 log10
gEq/mg (range=1.6-2.79 gEq/mg) and of 1.99 log10
gEq/mg (range: 1.56-3.13gEq/mg), respectively (Table II).
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Table II. Summary of polyomavirus detection and characteristics in all clinical specimens.
Cancerous Benign  Plasma PBMCs Urine 
prostate tissue prostate tissue
BKV+/BK− 6/20 1/25 6/18 (+2 NP) 2/22 (+2 NP) 7/17 (+2 NP) 
Mean BKV load (range)§ 3.35 (2.26-3.90) 1.54 3.25 (2.44-4.25) 1.15 (1.11-1.18) 2.97 (2.34-4.85) 
NCCR sequence Prototype Prototype with  5 Prototype 1  1 Prototype Prototype 
R-block deletion Prototype with 1 Prototype with 
(DDP-like strain) R-block deletion  R-block deletion
(DDP-like strain) (DDP-like strain)
Genotype Subtype I/b-2 Subtype I/b-2 4 Subtype II, Subtype I/b-2 3 Subtype II, 
2 subtype I/b-2 4 subtype I/b-2
JCV+/JCV− 14/12 14/12 2/21 (+2 NP) 14/10 (+2 NP) 15/9 (+2 NP) 
Mean JCV load  (range)§ 2.04 (1.60-2.79)  1.99 (1.56-3.13) 3.81 (3.76-3.86) 1.29 (1.11-1.45)  5.16 (3.43-6.51) 
NCCR sequence Archetype Archetype Archetype Archetype Archetype 
Genotype 2 Type 3A, 1 Type 3A, Type 1B 1 Type 3A, 2 Type 3A,
7 type 1B, 9 type 1B, 8 type 1B, 9 type 1B,
5 type 1A 3 type 1A, 4 type 1A, 3 type 1A,
1 type 4 1 type 4 1 type 4
p-Value* 0.002 0.001 
NP: Not provided; BKV: BK virus; DDP: BKV strain (GenBank: U91605.1); JCV: JC virus; NCCR: non-coding control region; PBMCs: peripheral
blood mononuclear cells. *By Mann–Whitney U-test. p-Value <0.05 was considered statistically significant. §BKV and JCV loads are the mean
(range) of log10 genome equivalent (gEq)/ml in urine and in plasma, as mean (range) of log10 gEq/106 cells in PBMCs and as mean (range) of log10
genome equivalent (gEq)/mg in tissues. 
Statistical analysis of these data highlighted that the
average number of genome equivalents of BKV detected in
cancerous prostate tissues was significantly higher than that
observed in JCV-positive ones (p=0.002) (Table II). A
statistically significant difference between BKV and JCV
loads in malignant tissues was observed even when the
results were categorized according to the Gleason score 6
and 7. In fact, the mean BKV load reported in the Gleason 7
class was significantly higher than that stated for JCV
(p=0.013) (Table III). However, the difference among the
mean JC and BK loads was not statistically significant in the
Gleason 6 class, although the number of BKV genome
equivalents in cancerous prostatic tissue specimens was
higher than that of JCV (p=0.053) (Table III).
Conversely, the average number of BKV genome
equivalents detected in urine was significantly lower than
that observed in JCV-positive urine (p=0.001) (Table II).
Even when the data were partitioned into the two Gleason
score classes, the BKV load in urine specimens was
significantly lower than that of JCV in both classes (Table
III). However, the comparison between the mean values of
JCV and BKV loads in urine by Gleason score was not
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Table III. Human polyomaviruses characteristics in all clinical specimens provided according to Gleason score. 
Cancerous prostate Benign prostate Plasma PBMCs Urine 
tissue tissue 
Gleason 7
BKV+/BKV− 4/10 1/13 3/10 (+1 NP) 2/11 (+1 NP) 4/9 (+1 NP)
Mean BKV load (range) 3.44 (2.26-3.90) 1.54 3.26 (2.44-4.25) 1.15 (1.11-1.18) 2.61 (2.34-3.01)
NCCR sequence Prototype Prototype with  2 Prototype 1 Prototype Prototype 2
R-block deletion 1 Prototype with R-block 1 Prototype with R-block 
(DDP-like strain) deletion (DDP-like strain) deletion (DDP-like strain)
Genotype Subtype I/b-2 Subtype I/b-2 1 Subtype II; Subtype I/b-2 Subtype II
1 Subtype I/b-2 2 Subtype I/b-2 
Gleason 7
JCV+/JCV− 9/5 6/8 1/12 (+1 NP) 7/6 (+1 NP) 7/5 (+2 NP)
Mean JCV load (range) 1.99 (1.6-2.65) 2.11 (1.79-3.13) 3.76 1.24 (1.11-1.45) 4.75 (3.43-6.51)
NCCR sequence Archetype Archetype Archetype Archetype Archetype
Genotype 2 type 3A, 1 Type 3A, 1 Type 1B 1 Type 3A, 2 type 3A,
4 type 1B, 2 type 1B, 2 type 1B, 2 type 1B,
3 type 1A 2 type 1A,  4 type 1 2 type 1A
1 type 4
p-Value* 0.013 0.008 
Gleason 6
BKV+/BKV− 2/9 0/11 3/7 (+1 NP) 0/10 (+1 NP) 3/7 (+1 NP)
Mean BKV load (range) 3.17 (3.08-3.26) / 3.25 (2.81-3.76) / 3.45 (2.47-4.85)
NCCR sequence / / Prototype / Prototype
Genotype / / 2 Subtype II, / 1 Subtype II
1 subtype I/b-2 2 subtype I/b-2
Gleason 6
JCV+/JCV− 5/6 7/4 1/9 (+1 NP) 6/4 (+1 NP) 8/3
Mean JCV load (range) 2.15 (1.63-2.79) 1.92 (1.56-2.21) 3.86 1.37 (1.23-1.45) 5.52 (3.78-6.35)
NCCR sequence Archetype Archetype Archetype Archetype Archetype
Genotype 4 Type 1B,   6 Type 1B,  1 Type 1B 5 Type 1B, 8 Type 1B 
1 type 1A 1 type 1A 1 type 1A
p-Value* 0.053 0.024 
NP: Not provided; BKV: BK virus; DDP: BKV strain (GenBank: U91605.1); JCV: JC virus; NCCR: non-coding control region; PBMCs: peripheral
blood mononuclear cells.*By Mann–Whitney U-test. p-Value <0.05 was considered statistically significant. §BKV and JCV loads values were
expressed as mean (range) of log10 genome equivalent (gEq)/ml in urine and in plasma, as mean (range) log10 gEq/106 cells in PBMC and as mean
(range) of log10 genome equivalent (gEq)/mg in tissues. 
statistically significant, although the number of genome
equivalents decreased from those with Gleason score 7 to
those with Gleason score 6 (data not shown).
Finally, categorizing the results according to the number
of patients and type of virus, JCV was detected in 22 out of
26 (84.6%) of the individuals, whereas BKV in 11 out of 26
(42.3%). Two patients were negative for both viruses.
Therefore, JCV was more common than BKV in the cohort
of patients enrolled in this study.
Analysis of JCV and BKV NCCR sequences. All the
specimens that were positive for viral DNA in the initial
screening were further analyzed for the presence of re-
arrangements within the NCCR region of both viruses. The
NCCR sequences amplified in each BKV-positive clinical
sample were compared to the prototypic NCCR defined by
Yogo et al. (41), which spans from the midpoint of the origin
of replication and the start site of the agno protein gene.
Specifically, the 268 nucleotides of the prototypic NCCR
sequence were arbitrarily divided into five blocks (O, P, Q,
R, and S) with lengths of 35, 68, 39, 63, and 63 nucleotides,
respectively, to describe the major rearrangements within this
region more easily.
Homology sequence analysis evidenced that the BKV
NCCR sequence isolated from the urine of four patients was
identical to the prototypic NCCR, consisting of a single
complete copy of the five blocks arranged in the correct order,
with the occurrence of a few point-mutations at nucleotide
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Figure 1. Alignment of BKV NCCR isolates with the prototypic NCCR sequence. The prototypic NCCR defined by Yogo and colleagues (41) is shown
at the top of the figure, while nucleotide sequences of three variants, determined directly from prostatic tissue, urine and blood samples, are shown
below in relation to the prototypic NCCR, with nucleotide substitutions indicated by bold highlighted letters and deletions identified by bold
highlighted hyphens. The genotype/subtype corresponding to each isolate is also indicated. Blocks (P, Q, R and S) commonly used to denote
archetypal NCCRs (27) are indicated under the NCCR sequences, while proven and putative binding sites for transcriptional factors are illustrated
above the prototypic NCCR sequence. The O-block, containing the origin of replication, was omitted.
positions 4 within R-block and 18 within S-block, and a
thymidine nucleotide deletion at nucleotide position 50 within
S-block. These point mutations did not involve any cellular
transcriptional factors binding site, except for the single-
nucleotide deletion at position 50 within S-block involving
the estrogen response element (Figure 1, isolate A). A
prototypic NCCR structure was also isolated from three urine
and four plasma specimens belonging to five patients. All
sequences were characterized by various nucleotide
substitutions at nucleotide positions 55 within P-block, 7 and
41 within R-block, 24 within S-block and by the deletion of
a single adenine nucleotide at nucleotide position 58 within
P-block. The nucleotide substitutions at position 55 within P-
block and 41 within R-block involved the binding sites for
the cellular factors p53 and NF-1, respectively, whereas the
adenine deletion at position 58 within P block interested the
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Figure 2. Examples of nucleotide sequence diversity in JCV NCCR isolates from different clinical specimens of patients with PC. The NCCR sequence
of the archetypal JCV strain CY, as proposed by Yogo et al. (31), is shown at the top of the figure and the consensus sequences of the NCCR isolated
from cancerous or normal prostatic tissues (CPT and NPT, respectively), blood and urine specimens of three patients with PC, with related genotype,
are shown below. The four nucleotide changes (G108A, A133C, G213C, G217A), identified by comparing with CY isolate, are indicated by bold
highlighted letters. The JCV NCCR isolated from specimens of the other patients always included the nucleotide substitution G217A (data not
shown). The six boxes commonly used to divide the archetypal NCCR (33) are indicated under the NCCR sequences, while proven and putative
binding sites for transcriptional factors are illustrated above the CY NCCR sequence.
binding site for the transcriptional factor c-myc (Figure 1,
isolate B). Finally, two patients showed a rearranged NCCR
structure: the former in benign prostatic tissue samples,
whereas the latter in plasma and PBMCs specimens. This re-
arranged NCCR consisted of a whole R-block deletion and of
a perfectly conserved single copy of the remaining P, Q and S
blocks arranged in the correct order. The R-block deletion
results in the loss of the NF-1 binding site. This re-arranged
sequence was also characterized by the same two nucleotide
changes within the S-block found in isolate A: the nucleotide
transition at position 18, which did not involve any cellular
transcriptional factors binding site, and the thymidine deletion
at nucleotide position 50, involving the estrogen response
element binding site (Figure 1, isolate C). This rearranged
sequence was similar to the DDP strain of BK virus isolated
from PBMCs by Degener and colleagues (44).
Regarding JCV, the archetypal variant type II-S, with a few
single-nucleotide substitutions, has been found in all samples.
In particular, four nucleotide changes (G108A, A133C,
G213C and G217A), identified in the NCCR from 10 isolates
of three patients by comparing with the archetypal JCV CY
strain, have been described previously by Agostini et al. (13)
and Zambrano et al. (45) and correspond to sequence
polymorphisms (Figure 2). The nucleotide changes G108A
and A133C did not involve any cellular transcriptional factors
binding site, whereas the nucleotide substitutions G213C and
G217A involved nuclear factor-1(NF-1) binding site. The
NCCR sequences isolated from specimens of the remaining
JCV-positive patients were all characterized by the 217-G to
A nucleotide transition inside the box F (data not shown).
PCR and sequence analysis of BKV/JCV VP1 region. An
additional specific nested-PCR was undertaken to detect the
presence of VP1 typing region in all BKV- and JCV-positive
samples. Regarding BKV, the 327 bp VP1 gene sequence
was amplified in clinical specimens belonging to 11 patients
(Table II). The amplified PCR products were sequenced in
order to classify each BKV strain into the corresponding
subtype/subgroup, analyzing the SNPs within the amplified
VP1 region and aligning our 327 bp typing isolates with the
consensus sequences generated for each BKV subtype/
subgroup (28). Based on the SNPs and on the consensus
sequences, subtype I/subgroup b-2 was detected in six
patients, while subtype II was detected in five individuals.
The SNPs and the consensus sequence, generated from the
alignment of 32 complete JCV genomes (42), were used to
determine the JCV genotype of our positive samples. In
particular, among the 26 enrolled patients, a prevalence of
the European genotypes 1A, 1B and 4, followed by the
African genotype 3A, was observed. In particular, genotypes
1A and 1B were found in six and in 13 individuals,
respectively, whereas type 4 was identified in one patient.
Finally, two patients carried the African genotype 3A.
Discussion
The human prostate is a organ recognized without normal
flora. However, different infectious agents have been shown
to affect the prostate and cause both asymptomatic and
symptomatic diseases, especially prostatitis. Currently, there
is both experimental and clinical evidence validating the
hypothesis that infection-induced chronic inflammation of
the prostate may be one of the many causes of PC.
Moreover, there is an indication that men who have used
anti-inflammatory drugs have a reduced risk of PC, and that
the use of antibiotics may result in a declined rate of chronic
prostate inflammation. This further demonstrates a strong
link between infection and chronic prostate inflammation,
suggesting that infectious agents may have a link to prostate
carcinogenesis (3). However, the limited number of studies
conducted over the past few years to define viral infections
as a risk factor in PC development has yielded rather
inconclusive data (22, 24).
BK virus is among several non-sexually transmitted
infectious agents investigated in relation to prostate
carcinogenesis. BKV, a member of the Polyomaviridae
family, is widely distributed in the human population.
Following primary infection, typically acquired during early
childhood, the virus disseminates into various organs and
establishes a persistent infection, predominantly in the
kidney and the genitourinary tract, including the prostate (8,
10, 22). Since BKV possesses potentially oncogenic
properties, and it is associated with long-term latency and
genitourinary tropism, several studies investigated its
possible link to PC with controversial results (13-25). In the
literature, there are reports on a positive correlation between
BKV DNA and PC (14, 15, 18, 19, 24, 25). Among these,
Das et al. (18), Russo et al. (19), Delbue et al. (24) and
Mischitelli et al. (25) found that BKV DNA positivity was
more common in malignant than in normal prostatic tissue.
However, the intriguing hypothesis that BKV might
contribute to prostate carcinogenesis has not been supported
by the results of other molecular studies: one observed no
difference in BKV DNA positivity between malignant and
benign tissue specimens (29), whereas others observed
minimal or no evidence of BKV DNA in prostate tissue
specimens (16, 17, 20-23). In this study, the percentage of
BKV DNA-positive cancerous prostate tissues (23%) is
lower than those reported in our previous reports (19, 25), in
which BKV genome was found in 22/26 (85%) and in 31/71
(44%) fresh PC specimens, respectively. However, this
percentage is similar to that reported by Balis and colleagues
(15), who revealed the presence of BK virus in 19% of all
PC cases. It is not clear why there has been such a variation
in the percentage of BKV DNA-positive malignant prostate
tissues among our three study populations, as we used the
same methodological assay to evaluate BKV load in clinical
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specimens. This discrepancy may be due to the different
number of Gleason score classes in these studies. In fact, in
Russo et al. (19) and in Mischitelli et al. (25) the data were
scheduled into four Gleason score classes, spanning from
Gleason 6 and Gleason 9, whereas in this study they were
categorized in only two classes: Gleason 6 and 7. The main
BKV DNA positivity in PC biopsies was found in the highest
Gleason score classes (8 and 9), whereas the lowest
frequencies of viral positivity were reported within the
classes with Gleason score 6 and 7, especially in that with
Gleason 6. The latter result is in agreement with data
reported by this study, in which the lowest BKV positivity
and mean load were detected in patients with a Gleason
score of 6 (Table III). This led us to speculate that BKV
might interfere with the control of cellular proliferation,
promoting the acquisition of a complete ‘neoplastic
phenotype’ and tumor progression. Moreover, the possibility
of a ‘hit and run’ carcinogenic mechanism induced by BKV
cannot be excluded (18). Even the prevalence of BKV DNA
in plasma and urine specimens from patients with PC
belonging to this study group (viremia 25% and viruria
29.2%) was lower with respect to that (viremia 31% and
viruria 54%) detected by Russo et al. in 2008 (19).
Nevertheless, both studies demonstrated that the urinary
compartment was the preferential site of BKV replication.
Despite the high structural homology between BKV and
the human polyomavirus JC, the latency site in the
genitourinary tract and the potential oncogenicity associated
with these viruses, only a few studies have investigated JCV
in relation to PC obtaining contradictory data (13, 16, 21,
24). Therefore, we extended this study to investigate a
possible causative role of JCV in PC development. Our
results showed the presence of JCV DNA in 58.3% of
cancerous and benign prostatic tissue samples, whereas JC
viruria and viremia were found in 62.5% and 8.3% of
patients with PC, respectively. Similarly to BKV, major
replication in the urinary compartment was observed.
However, JC viruria was significantly higher than that of
BKV (Table II), even when the results were categorized
according to Gleason score (Table III). Therefore, JCV was
more common than BKV in the cohort of patients with PC
enrolled in this study, even though the average number of
BKV genome equivalents in cancerous prostatic tissue
specimens was higher than that of JCV (p=0.002).
These results are consistent with the data reported by
Zambrano et al., who detected JCV in 50% of 12 patients
with PC either in prostatic tissues or in urine specimens (13).
Two independent studies, in contrast, did not find significant
differences in JCV detection between cancerous and benign
prostatic tissue specimens screened (16, 24). Similarly, a
Mexican study did not detect JCV sequences in any of the
55 prostate cancer biopsies analyzed (21). Discrepancies
among these studies, including ours, may be explained by
technical differences in the viral detection methods and
differences in sample size. Actually, the difficulty in
obtaining fresh surgical tissues limited the statistical
considerations of our data due to the low numbers of samples
collected for this study and the previous one (19). In fact,
only one biopsy specimen of normal and cancerous prostatic
tissue from each patient was tested.
The purpose of the histological division of the prostatic
tissue specimens was to examine whether a specific BKV
and JCV NCCR configuration was associated with a normal
or cancerous cellular environment. As mentioned above, the
NCCR of both human polyomaviruses BK and JC is a highly
variable region, which may undergo sequence
rearrangements yielding viral variants that could up-
modulate viral expression in a specific anatomical site or
acquire new tissue tropism and greater pathogenic potential.
Monini and colleagues reported the detection of BKV
sequences by PCR and Southern blotting in more than 50%
of both normal and tumor tissues obtained from the urinary
tract and prostate (29). The sequence analysis of these BKV
regulatory regions showed that these tissues were infected by
a novel BKV strain, URO1. URO1 strain, which has a high
prevalence in the urinary tract of Italian patients, is
characterized by NCCR rearrangements that may affect viral
DNA replication. However, it remains to be determined
whether the mutations in URO1 have an effect on replication
or transformation (46). Recently, Mischitelli et al. found two
rearranged BKV variants, characterized by enhancement of
the oncogenic c-myc and the oncosuppressor p53 binding
sites, in cancerous tissues of two patients affected by
advanced prostate cancer (25).
In this study, a DDP-like NCCR sequence was isolated
from the normal prostatic tissue and the blood (plasma and
PBMCs) of two BKV-positive patients. This rearranged
NCCR consisted of a whole R-block deletion and of a
perfectly conserved single copy of the remaining O, P, Q and
S blocks arranged in the correct order (Figure 1). The
simultaneous presence of a rearranged NCCR sequence in
plasma and in PBMCs of the same patient could likely be
explained by the occurrence of an alteration in the BKV
NCCR structure during persistent infection in the circulatory
compartment. This led us to speculate that in this case, the
BK variant found in plasma could derive from the rearranged
one recovered in PBMCs. This suspicion was confirmed by
the NCCR sequencing of the viral variant isolated from the
urine of this patient. In fact, the excreted virus showed a
prototypical structural organization of its regulatory region,
consisting of a single complete copy of all five blocks (O, P,
Q, R and S).
The molecular analysis of the BKV VP1 coding sequence
between nucleotides 1744 and 1812 (amino acids 61 to 83)
allows definition of the BKV genotypes and their different
distribution in human populations (37). In particular, subtype
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I (further divided into four subgroups, each of which has a
unique geographical distribution pattern: I/a, I/b-1, I/b-2 and
I/c) is widespread throughout the world, subtype IV (further
divided into six subgroups with their own geographical
distribution pattern: IV/a-1, IV/a-2, IV/b-1, IV/b-2, IV/c-1
and IV/c-2) is prevalent in East Asia and part of Europe,
while subtypes II and III are rarely detected throughout the
world (47). In this study the European subtype I/b-2 and the
subtype II were mainly detected. Interestingly, all BKV
subtypes/subgroups are defined by the presence of specific
nucleotide substitutions and deletions within the NCCR
sequence (41). In fact, alignment of all NCCR sequences,
isolated from each BKV-positive clinical sample of our
patients with PC, with the prototypic NCCR sequence
proposed by Yogo and colleagues (41), revealed that the
point mutations detected in these sequence, including the
rearranged ones, were typical of the consensus NCCR
sequences identified for the BKV subtype I/subgroup b-2 and
subtype II.
Concerning JCV, Laghi et al. (48) and Ricciardiello et al.
(49) demonstrated that the pathogenic JCV Mad-1 strain was
the only JCV variant present in the human colon and that a
variant with a single 98-bp sequence within the NCCR is
found exclusively in the cancer tissues, suggesting that this
Mad-1-like strain might be implicated in the development of
chromosomal instability in the colon epithelium. It is
noteworthy that JCV Mad-1 was also detected in the prostate
gland associated with the urinary tract, where archetypal
strains would be expected. Different NCCR sequences were
also found in prostatic tissue together with JCV Mad-1,
suggesting that prostate may be inhabited by more than one
JCV strain or NCCR variant (13). In our study, when JCV was
present in histologically different areas, the NCCR sequencing
showed that in all cases, the virus was identical to the
archetypal variant type II-S in both normal and cancerous
areas (Figure 2). The finding of archetypal NCCR structures
within our cancerous and benign prostate tissues led us to
speculate that the non-pathogenic CY strain of JCV might be
selected for replication and persistently infect the prostate
gland, mostly the portion associated with the urinary tract.
Alterations in the prostatic microenvironment could allow the
virus to actively replicate and select for one or more JCV
strains or NCCR variants that are capable of transforming the
host tissue. Ongoing replication of the virus might also lead
to viral and cellular modifications that could promote genomic
instability, contributing to tumorigenesis or cancer progression.
This hypothesis is supported by Zambrano et al., who
observed different NCCR variants in the prostate tissue and in
urine of one patient (13). It is possible that JCV could mainly
be involved in cancer progression rather than in tumorigenesis,
since we detected the virus in an archetypal form in prostate
tissues belonging to patients affected by Gleason 7 PC.
However, this suspicion must be confirmed by further studies.
Four nucleotide changes (G108A, A133C, G213C and
G217A) were detected in the NCCR from 10 isolates of three
patients by comparing with the archetypal JCV CY strain
(31). All these changes corresponded to known sequence
polymorphisms (13, 45), and two of them (G213C and
G217A) involved the NF-1 binding site (Figure 2). The 217-
G to A nucleotide transition inside box F was also present
within the NCCR sequences isolated from specimens of the
other JCV-positive patients. This point-mutation seems to be
a common feature of the European strains and was also
found in European Americans (45). Indeed, in our study
group, there was a prevalence of the European genotypes 1A,
1B and 4, followed by the East African genotype 3A.
Although in this study the sample size was small, our data
demonstrate the presence of JCV DNA in approximatively
60% of tumor and benign prostatic tissue samples,
confirming the conclusions of a previous study in which JCV
was defined as a common inhabitant of the prostate. Even
though the detection of viral nucleic acids within the tumor
tissue is crucial, but not sufficient, in demonstrating any
potential involvement of viral infection in human cancer, the
finding of a high frequency of JCV DNA in prostate tissue
opens the discussion about its potential role in PC. However,
more studies are necessary to ascertain how a mainly
neurotropic virus such as JCV could operate in PC
development and progression, especially through
rearrangements of its regulatory region.
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